
Marco Galardini appointed W2 professor at TWINCORE
Inaugural lecture on 6 March 2026

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
The LISA Summer School 2026 takes place from 23 August to 11 September 2026. Registration is open until 31 March.

Inaugural lecture on 6 March 2026

Some extension numbers have changed.

zukunft.niedersachsen provides €2.7 million in funding for joint project on rare diseases
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Waqas F, S da Costa L, Zapatero-Belinchón F, Carter-Timofte M, Lasswitz L, van der Horst D, Möller R, Dahlmann J, Olmer R, Geffers R, Gerold G, Olagnier D, Pessler F
Elwy A, Abdelrahman H, Specht J, Ewert G, Friebus-Kardash J, Dhiman S, Falkenstein J, Christ T, Wiebeck E, Shamoon A, Leimkühler N, Gramberg T, Russ A, Kalinke U, Kuang F, Sutter K, Kopf M, Mack M, Hansen W, Nimmerjahn F, Lang K
Zhang Y, Matzaraki V, Vadaq N, Blaauw M, Vos W, Groenendijk A, van Eekeren L, Stalenhoef J, Berrevoets M, Rokx C, Delporte M, Otten T, Joosten L, Xu C, Li Y, Vandekerckhove L, van der Ven A, Netea M
The project will investigate the immunological and genetic causes of vaccination failure in 5% of HBV-vaccinated individuals in order to develop new strategies to improve vaccination protection.
We are investigating how the association of HCV with lipoproteins contributes to the persistence of the virus by influencing entry into liver cells and protecting against antibodies. The aim is to gain new insights for the development of an HCV vaccine.
Human, potentially neutralizing antibodies against HEV have advanced the development of new detection methods for the virus in patient samples. Serological and functional analyses are used to determine markers for the course and treatment of chronic infections.
We are investigating how genetic variants influence the risk of severe RSV infections in infants. Exome sequencing and bioinformatic analyses are used to identify causal variants in immunity genes.

